Literature DB >> 23689562

Primary glomerulonephritis in mainland China: an overview.

Jingyuan Xie1, Nan Chen.   

Abstract

Chronic kidney disease (CKD) has received increased attention as a global health problem because of its increasing incidence and prevalence, poor outcome and high associated costs. Primary glomerulonephritis (GN) is the leading cause of CKD and end-stage renal disease in China. Immunoglobulin A nephropathy (IgAN) is the most common type of primary GN and accounts for 40-50% of the adult patients undergoing renal biopsy. Interestingly, the reported prevalence of focal segmental glomerulosclerosis (FSGS) in China varies by geographical region, and the prevalence of membranous nephropathy is increasing. Familial FSGS and IgAN are common in China, suggesting that genetic factors are involved in their pathogenesis. The evidence to guide the treatment of these glomerular diseases is limited. Most Chinese nephrologists follow the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines during their practice. Here, we review the current prevalence, etiology, clinicopathological features and treatment of primary GN in China.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2013        PMID: 23689562     DOI: 10.1159/000348642

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  19 in total

Review 1.  Genetic basis of adult-onset nephrotic syndrome and focal segmental glomerulosclerosis.

Authors:  Jian Liu; Weiming Wang
Journal:  Front Med       Date:  2017-08-03       Impact factor: 4.592

2.  Novel mutations in the inverted formin 2 gene of Chinese families contribute to focal segmental glomerulosclerosis.

Authors:  Jingyuan Xie; Xu Hao; Evren U Azeloglu; Hong Ren; Zhaohui Wang; Jun Ma; Jian Liu; Xiaodan Ma; Weiming Wang; Xiaoxia Pan; Wen Zhang; Fang Zhong; Yifu Li; Guoyu Meng; Krzysztof Kiryluk; John Cijiang He; Ali G Gharavi; Nan Chen
Journal:  Kidney Int       Date:  2015-06-03       Impact factor: 10.612

3.  Comparative analysis of membranous and other nephropathy subtypes and establishment of a diagnostic model.

Authors:  Hanyu Zhu; Bo Fu; Yong Wang; Jing Gao; Qiuxia Han; Wenjia Geng; Xiaoli Yang; Guangyan Cai; Xiangmei Chen; Dong Zhang
Journal:  Front Med       Date:  2018-08-10       Impact factor: 4.592

Review 4.  Management of Membranous Nephropathy in Asia.

Authors:  Jing Xu; Xiaofan Hu; Jingyuan Xie; Nan Chen
Journal:  Kidney Dis (Basel)       Date:  2015-09-01

5.  A noninvasive artificial neural network model to predict IgA nephropathy risk in Chinese population.

Authors:  Jie Hou; Shaojie Fu; Xueyao Wang; Juan Liu; Zhonggao Xu
Journal:  Sci Rep       Date:  2022-05-18       Impact factor: 4.996

6.  DTI for the assessment of disease stage in patients with glomerulonephritis--correlation with renal histology.

Authors:  Qiang Feng; Zhijun Ma; Jianlin Wu; Wei Fang
Journal:  Eur Radiol       Date:  2014-07-21       Impact factor: 5.315

7.  Glucocorticoids in the treatment of patients with primary focal segmental glomerulosclerosis and moderate proteinuria.

Authors:  Jianni Huang; Li Lin; Jingyuan Xie; Xiao Li; Pingyan Shen; Xiaoxia Pan; Hong Ren; Nan Chen
Journal:  Clin Exp Nephrol       Date:  2018-05-14       Impact factor: 2.801

8.  Shenhua Tablet inhibits mesangial cell proliferation in rats with chronic anti-Thy-1 nephritis.

Authors:  Wenjia Geng; Ribao Wei; Shuwen Liu; Li Tang; Hanyu Zhu; Pu Chen; Jie Wu; Xueguang Zhang; Fei Zhu; Zhong Yin; Xiangmei Chen
Journal:  Biol Res       Date:  2016-03-11       Impact factor: 5.612

9.  Serum C3 and Renal Outcome in Patients with Primary Focal Segmental Glomerulosclerosis.

Authors:  Jian Liu; Jingyuan Xie; Xiaoyan Zhang; Jun Tong; Xu Hao; Hong Ren; Weiming Wang; Nan Chen
Journal:  Sci Rep       Date:  2017-06-22       Impact factor: 4.379

10.  Biomarkers to detect membranous nephropathy in Chinese patients.

Authors:  Li Lin; Wei Ming Wang; Xiao Xia Pan; Jing Xu; Chen Ni Gao; Wen Zhang; Hong Ren; Jing Yuan Xie; Pin Yan Shen; Yao Wen Xu; Li Yan Ni; Nan Chen
Journal:  Oncotarget       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.